Stage 2 · Toolkit 2.1
Nonclinical Development Plan & IND/CTA-Enabling Strategy
Define the nonclinical package needed to support IND, CTA, first-in-human, and clinical development.
What it helps control
Operational support
Helps teams establish the procedures, working records, trackers, and evidence needed for Nonclinical Development Plan & IND/CTA-Enabling Strategy.
How it helps your team
Surface evidence gaps and dependencies before they delay IND, CTA, or first-in-human decisions.
Designed for
Nonclinical development, toxicology, safety pharmacology, bioanalysis, Regulatory Affairs, and Quality teams.
Included files
Know exactly what the toolkit contains
The file names below show what is included. File contents become available only after purchase.
Word documents
- Nonclinical Development Plan Template
- IND/CTA-Enabling Study Strategy
- Nonclinical Gap Assessment Template
- Nonclinical Study Justification Memo
- Nonclinical Submission Readiness Checklist
- Preclinical-to-Clinical Transition Guidance
- Nonclinical Evidence Summary Template
- Go / No-Go Decision Memo
Excel workbooks
- Nonclinical Study Plan Tracker
- IND/CTA Evidence Matrix
- Nonclinical Gap Tracker
- Study Dependency Tracker
- Submission Readiness Tracker
- Source Data Reference Log
Related toolkits
Continue within stage 2
GLP Compliance & Sponsor Oversight
Ensure GLP studies are appropriately planned, overseen, monitored, documented, reported, and archived.
2.3Toxicology Study Planning & Management
Manage toxicology studies and interpret key findings for regulatory and FIH readiness.
2.4Safety Pharmacology Program
Assess safety pharmacology risks, including cardiovascular, respiratory, and CNS risk.